News | September 29, 2009

Multaq (dronedarone) Recommended for European Approval

September 28, 2009 – Sanofi-aventis announced last week the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq (dronedarone 400mg tablets).

The CHMP has recommended the approval of Multaq in adult clinically stable patients with history of, or current nonpermanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate.

In the Summary of Positive Opinion, the CHMP has acknowledged that dronedarone has been shown, in addition to its rhythm and rate controlling properties, to decrease the risk of atrial fibrillation-related hospitalizations.

The positive opinion from the CHMP needs now to be ratified by the European Commission. The opinion is based on the submission of a comprehensive clinical data package including seven international, multicenter, randomized clinical trials involving more than 7,000 patients and including the landmark ATHENA trial.

The ATHENA trial involved 4,628 patients with atrial fibrillation/atrial futter or a recent history of these conditions and showed that Multaq (dronedarone) in addition to standard therapy, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24 percent when compared to placebo, meeting the study’s primary endpoint. Reported significant adverse events in the Multaq arm included diarrhea, nausea, bradycardia, QT-interval prolongation and cutaneous rash.

The incidence of atrial fibrillation is growing worldwide in relation to aging populations. It is emerging as a public health concern and affects about 4.5 million people and represents one-third of hospitalizations for arrhythmia in the European Union.

Multaq recently received approval from the U.S. Food and Drug Administration (FDA), Health Canada and Swissmedic (Swiss Health Authority).

www.dronedarone-atrial-fibrillation-pressoffice.com

Related Content

News | Pharmaceuticals

January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...

Home January 05, 2022
Home
News | Pharmaceuticals

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first small ...

Home January 04, 2022
Home
News | Pharmaceuticals

December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...

Home December 16, 2021
Home
Videos | Pharmaceuticals

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at ...

Home November 22, 2021
Home
News | Pharmaceuticals

November 19, 2021 — Results from two early clinical studies show the first version of an oral PCSK9-inhibitor ...

Home November 19, 2021
Home
News | Pharmaceuticals

November 15, 2021 — Esperion announced the presentation of three abstracts highlighting Nexletol tablets at the American ...

Home November 15, 2021
Home
News | Pharmaceuticals

November 15, 2021 — Novartis announced results from a pooled post-hoc analysis of Phase III ORION-9, -10 and -11 trials ...

Home November 15, 2021
Home
Feature | Pharmaceuticals | By Dave Fornell, DAIC Editor

There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart ...

Home October 13, 2021
Home
News | Pharmaceuticals

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

Home October 07, 2021
Home
News | Pharmaceuticals

May 15, 2021 — A new analysis of the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in ...

Home May 15, 2021
Home
Subscribe Now